Circulating intercellular adhesion molecule-1 (ICAM-1) in patients with hepatolithiasis

Area of Science:

• Hepatobiliary Medicine
• Immunology
• Biochemistry

Background:

• Hepatolithiasis, characterized by bile duct stones in the liver, is associated with significant morbidity.
• The pathogenesis of hepatolithiasis involves complex interactions including inflammation, infection, and bile stasis.
• Circulating intercellular adhesion molecule-1 (sICAM-1) is a marker of endothelial activation and inflammation.

Purpose of the Study:

• To investigate the role of circulating intercellular adhesion molecule-1 (sICAM-1) in the pathogenesis of hepatolithiasis.
• To compare sICAM-1 levels in patients with hepatolithiasis to healthy controls.
• To assess changes in sICAM-1 levels following surgical clearance of bile duct stones.

Main Methods:

• Serum sICAM-1 concentrations were measured using a sandwich enzyme immunoassay in 40 hepatolithiasis patients and 15 healthy controls.
• Blood samples were collected before surgery and at least three months after stone clearance.
• Bile cultures and detailed cholangiography reviews were performed to assess infection and intrahepatic strictures.

Main Results:

• Pre-operative sICAM-1 levels were significantly higher in hepatolithiasis patients (834 +/- 128 ng/ml) compared to controls (346 +/- 68 ng/ml).
• Post-treatment sICAM-1 levels decreased significantly (677 +/- 139 ng/ml) but remained elevated compared to controls.
• All patients had bile infections, and 82.5% showed intrahepatic strictures on cholangiography.

Conclusions:

• Elevated circulating intercellular adhesion molecule-1 (sICAM-1) is associated with hepatolithiasis, suggesting its involvement in the disease process.
• While stone removal reduces sICAM-1 levels, persistent elevation indicates ongoing inflammatory processes.
• Further research is warranted to fully elucidate the role of sICAM-1 in hepatolithiasis pathogenesis.